A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial - Timothy Devos; Tatjana Geukens; Alexander Schauvlieghe; Kevin K. Ariën; Cyril Barbezange; Myriam Cleeren; Veerle Compernolle; Nicolas Dauby; Daniël Desmecht; David Grimaldi; Bart N. Lambrecht; Anne Luyten; et al. (Trials, 2020)